Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
Cancer Treatment Reviews · 2024-05 · 126 · 102724
DOI: 10.1016/j.ctrv.2024.102724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-05. Verfasst von Christopher Grant und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Irvine Medical Center, Orange CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, ErbB Receptors. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California Irvine Medical Center, Orange CA, USA.
- Department of Medicine, University of California Irvine Medical Center, Orange CA, USA; Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange CA, USA. Electr…
Zitieren
APA
Grant, C., & Nagasaka, M. (2024). Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer. Cancer Treatment Reviews, 126, 102724. https://doi.org/10.1016/j.ctrv.2024.102724
Vancouver
Grant C, Nagasaka M. Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer. Cancer Treatment Reviews. 2024;126:102724. doi:10.1016/j.ctrv.2024.102724
BibTeX
@article{Grant2024,
author = {Grant, Christopher and Nagasaka, Misako},
title = {Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {126},
pages = {102724},
doi = {10.1016/j.ctrv.2024.102724}
}
EUVIMED